Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parambir Dulai

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Frontiers in Medicine|April 18, 2020
Predicting Response to Vedolizumab in Inflammatory Bowel DiseaseJoseph Meserve, Parambir Dulai
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2019
ReplyDavid Faleck, Parambir Dulai, Ryan Ungaro
Pancreas|October 29, 2021
Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record DatabasePatrick A Twohig, Enrique de-Madaria, Shyam Thakkar, et al.
Alimentary Pharmacology & Therapeutics|March 21, 2021
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' replySushrut Jangi, Hyuk Yoon, Parambir Dulai, et al.
Inflammatory Bowel Diseases|June 30, 2025
Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE TrialDhruv Ahuja, Sama Anvari, Emily C L Wong, et al.
Eclinicalmedicine|December 11, 2024
Corrigendum to "Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials" volume 72, 102621Sudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Eclinicalmedicine|May 10, 2024
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trialsSudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Therapeutic Advances in Gastroenterology|April 29, 2025
Comment on "Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis"Richard Kellermayer, Peter Lewindon, Cynthia Buness, et al.
Inflammatory Bowel Diseases|June 12, 2018
Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel DiseaseChristopher J Tyler, Tamara Pérez-Jeldres, Erik Ehinger, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Pangenome comparison of <i>Bacteroides fragilis</i> genomospecies unveil genetic diversity and ecological insightsRenee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Frontiers in Medicine|April 18, 2020
Predicting Response to Vedolizumab in Inflammatory Bowel DiseaseJoseph Meserve, Parambir Dulai
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 17, 2019
ReplyDavid Faleck, Parambir Dulai, Ryan Ungaro
Pancreas|October 29, 2021
Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record DatabasePatrick A Twohig, Enrique de-Madaria, Shyam Thakkar, et al.
Alimentary Pharmacology & Therapeutics|March 21, 2021
Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' replySushrut Jangi, Hyuk Yoon, Parambir Dulai, et al.
Inflammatory Bowel Diseases|June 30, 2025
Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE TrialDhruv Ahuja, Sama Anvari, Emily C L Wong, et al.
Eclinicalmedicine|December 11, 2024
Corrigendum to "Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials" volume 72, 102621Sudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Eclinicalmedicine|May 10, 2024
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trialsSudheer K Vuyyuru, Christopher Ma, Tran M Nguyen, et al.
Therapeutic Advances in Gastroenterology|April 29, 2025
Comment on "Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis"Richard Kellermayer, Peter Lewindon, Cynthia Buness, et al.
Inflammatory Bowel Diseases|June 12, 2018
Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel DiseaseChristopher J Tyler, Tamara Pérez-Jeldres, Erik Ehinger, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Pangenome comparison of <i>Bacteroides fragilis</i> genomospecies unveil genetic diversity and ecological insightsRenee E Oles, Marvic Carrillo Terrazas, Luke R Loomis, et al.
Pageof 2